Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease.
JHEP reports : innovation in hepatology（2023）
摘要
In patients with CLD vaccinated with two-dose vaccines, age, cirrhosis and type of vaccine (Vaxzevria > Pfizer BioNTech > Moderna) predict a "lower" humoral response, while viral hepatitis etiology and prior antiviral therapy predict a "higher" humoral response. This differential response appears not to associate with SARS-COV-2 infection incidence or vaccine efficacy. Still, compared with Wuhan-Hu-1, humoral immunity was lower for the Delta and Omicron variants, and all decreased after 6 months. As such, patients with CLD, particularly those older and with cirrhosis, should be prioritized for receiving booster doses and/or recently approved adapted vaccines.
更多查看译文
关键词
AASLD, American Association for the Study of Liver Diseases,ACE2, Angiotensin-Converting Enzyme 2,AIH, autoimmune hepatitis,CAID, cirrhosis-associated immune dysfunction,CHB, chronic hepatitis B,CLD, chronic liver disease,COVID-19 vaccine,Chronic liver disease,Cirrhosis,EASL, European Association for the Study of the Liver,Humoral immunity,IQR, interquartile range,MRFLD, metabolic related fatty liver disease,NAFLD, non-alcoholic fatty liver disease,NAb, neutralizing antibodies,OR, odds ratio,PBC, primary biliary cholangitis,PSC, primary sclerosing cholangitis,SARS-CoV-2,yo, years old
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要